desloratadine | Desal solution for oral administration 0, 5 mg / ml bottle 100 ml

Release form

oral solution

Packing

Bottle 100 ml.

Pharmacological action

Desal - a blocker of histamine H1 receptors (long-acting). It is the primary active metabolite of loratadine. Inhibits the release of histamine and C4 leukotriene from mast cells. Prevents development and facilitates the course of allergic reactions. It has anti-allergic, antipruritic and anti-exudative action. Reduces capillary permeability, prevents the development of tissue edema, relieves spasm of smooth muscles. It practically does not have a sedative effect and, when taken at a dose of 7.5 mg, does not affect the rate of psychomotor reactions. In comparative studies of desloratadine and loratadine, there were no qualitative or quantitative differences in the toxicity of the two drugs in comparable doses (taking into account the concentration of desloratadine).

Pharmacokinetics

After ingestion, it begins to be determined in plasma after 30 minutes. Food does not affect distribution. Bioavailability is proportional to the dose in the range from 5 mg to 20 mg. Plasma protein binding is 83-87%. It does not cross the blood-brain barrier (BBB). Intensively metabolized in the liver by hydroxylation with the formation of 3-OH-desloratadine, combined with glucuronide, only a small portion of the oral dose is excreted by the kidneys (less than 2%) and with feces (less than 7%).

Indications

Symptomatic treatment of seasonal and year-round allergic rhinitis, chronic idiopathic urticaria.

Contraindications

Hypersensitivity, pregnancy, breast-feeding. For syrup (in addition, due to the presence of sucrose and sorbitol in the composition): hereditarily transmitted fructose intolerance, impaired glucose / galactose absorption, or sucrose / isomaltose deficiency.

Composition of

active substance: desloratadine 0.5 mg

Dosage and administration

Adults and adolescents 12 years of age and older are prescribed orally, regardless of food intake, at a dose of 5 mg per day. Children aged 1 to 5 years - 1.25 mg once a day, aged 6 to 11 years - 2.5 mg once a day.

Side effects

Mental disturbances: hallucinations.

From the side of the central nervous system: dizziness, drowsiness, insomnia, psychomotor hyperactivity.

From the cardiovascular system: tachycardia, palpitations.

From the digestive system: abdominal pain, nausea, vomiting, dyspepsia, diarrhea.

From the liver and biliary tract: increased activity of liver enzymes, increased bilirubin concentration, hepatitis.

From the musculoskeletal system: myalgia.

Allergic reactions: anaphylaxis, angioedema, pruritus, rash, urticaria.

Storage conditions

Store in a dry, dark place, out of the reach of children, at a temperature not exceeding 25 РC.

Shelf life

2 years

Terms and conditions otpuska IZ drugstore

Without prescription

lekarstvennaja form

Solution for pryema inside

For

For adults, For children over 1 year old

Indications

Dermatitis, Allergic rhinitis, Nasuritis, Swelling of mucous membranes, Edema Allergy, Pollinosis, Pruritus

Specfar SA, Greece